Cognetivity Neurosciences Ltd. has entered into an agreement with Mitsui Sumitomo Aioi Life Insurance ("MSA") to work together to provide Cognetivity's artificial intelligence ("AI") powered technology (CognICATM) to MSA's policyholders through MSA's customer-facing web platform. The two companies will also begin negotiations to conclude a distributorship agreement by the end of June, 2023. MSA is the core company of the Japanese domestic life insurance business of the global MS&AD Insurance Group.

The company is headquartered in Tokyo and has approximately 2,500 employees. As of March 31, 2022, it had approximately 4 million policies in force with a value of $195.4 billion. Under the planned deployment, MSA policyholders will have personal access to Cognetivity's Integrated cognitive Assessment (CognICA) technology, an AI-powered brain health platform that can detect problems early, when they are more likely to be effectively addressed, as part of a proactive approach to customer health.

By detecting early, interventions can be done in a variety of ways depending on the individual requirements of the policyholder. According to Japan's Ministry of Health, Labour and Welfare, the number of people over 65 with dementia is expected to reach approximately 6.02 million by 2020 and will grow to 6.75 million by 2025. Cognetivity is achieving an important milestone by bringing its world-first technology to Japan, one of the larger and most important healthcare markets.

The agreement also demonstrates how Cognetivity's AI platform will help address some of the biggest healthcare challenges of time in screening and monitoring for brain health issues. More than half of the world's people with clinical-level mental health risks do not receive help for their challenges. However, with Cognetivity's technology, MSA's subscribers will be able to measure their own brain health, leading to early detection and treatment of dementia and other neurological and mental health issues.